Moderna’s mRNA-1273 is the third COVID-19 vaccine to be approved for use by the Medicines and Healthcare products Regulatory Agency (MHRA) and is the second mRNA vaccine after Pfizer/BioNTech ...

The company is seeking authorisation for a fourth dose of SpikeVax to any adult who has received an initial booster of any of the authorised or approved COVID-19 vaccines. Unlike Pfizer ...

Overall, Moderna said the safety profile is similar to the approved vaccine Spikevax. A detailed analysis of the late-stage ...

It looked at differences between patients given a Moderna booster after having had two jabs of the Pfizer vaccine and those who received the Pfizer vaccine three times. While about 70 percent of ...

Much to the consternation of parents, teachers and cruise ship enthusiasts, there are no approved treatments ... furthest along is Moderna, which has developed a norovirus vaccine with the same ...

The side effects of this booster shot are similar to those of the Moderna booster. However, research shows that people who ...

including an extensive pipeline of therapeutics in clinical trials that could be the booster shot the stock needs to generate a rebound. Let's discuss the pros and cons of buying Moderna stock.

The Spring Covid booster campaign will start on 1 April and run until 17 June. Vaccinations will be offered to: The NHS uses vaccines from two companies across the UK: Pfizer-BioNTech and Moderna.